(Q34409447)

2 August 2017

1 reference

title

Practical considerations on the use of rituximab in autoimmune neurological disorders (English)

1 reference

2 August 2017

1 reference

Mixalis L Kosmidis

1

1 reference

2 August 2017

Marinos C Dalakas

series ordinal

2

1 reference

2 August 2017

language of work or name

1 reference

1 March 2010

1 reference

Therapeutic advances in neurological disorders

2 August 2017

published in

1 reference

2 August 2017

volume

3

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

93-105

1 reference

Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Depletion of B lymphocytes from cerebral perivascular spaces by rituximab

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

A review of the current use of rituximab in autoimmune diseases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

B cells as therapeutic targets in autoimmune neurological disorders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Identification and development of new therapeutics for multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

6 July 2018

Spotlight on anti-CD20.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Isolated longitudinal myelitis: a report of six cases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Invited article: inhibition of B cell functions: implications for neurology

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Cytokine-producing B lymphocytes-key regulators of immunity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

The potential utility of B cell-directed biologic therapy in autoimmune diseases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

The immunopathology of multiple sclerosis: an overview

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Astrocytes are active players in cerebral innate immunity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Antigen presentation by B lymphocytes: how receptor signaling directs membrane trafficking

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

BCR ubiquitination controls BCR-mediated antigen processing and presentation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

B cells move to centre stage: novel opportunities for autoimmune disease treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Secondary progressive multiple sclerosis: current knowledge and future challenges

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Tolerability and safety of rituximab (MabThera).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Treatment of stiff person syndrome with rituximab.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Treatment of dys-immune neuropathies.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Defective B cell tolerance checkpoints in systemic lupus erythematosus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

From the bench to the bedside: ways to improve rituximab efficacy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Polymyositis and dermatomyositis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Complement activation determines the therapeutic activity of rituximab in vivo.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Chronic idiopathic ataxic neuropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Determinants of Human B Cell Migration Across Brain Endothelial Cells

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHY

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Worsening after rituximab treatment in anti-mag neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

An open label study of the effects of rituximab in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Response to therapy in myasthenia gravis with anti-MuSK antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Treatment of IgM antibody associated polyneuropathies using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjögren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Successful treatment of cardiac involvement in dermatomyositis with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609356135

Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Rituximab for refractory polymyositis: an open-label prospective study.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Rituximab as therapy for refractory polymyositis and dermatomyositis.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002645

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines

27 October 2018

1 reference

12 December 2020

Rituximab-responsive CIDP

1 reference

12 December 2020

Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies

1 reference

12 December 2020

Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura

1 reference

12 December 2020

A pilot trial of rituximab in the treatment of patients with dermatomyositis

1 reference

12 December 2020

Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients

1 reference

12 December 2020

Efficacy of rituximab in refractory polymyositis

1 reference

12 December 2020

1 reference

12 December 2020

Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report

1 reference

12 December 2020

Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M

1 reference

12 December 2020

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

12 December 2020

Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases

1 reference

12 December 2020

Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg

1 reference

12 December 2020

Rituximab for myasthenia gravis developing after bone marrow transplant

1 reference

12 December 2020

High-dose rituximab and anti-MAG-associated polyneuropathy

1 reference

12 December 2020

Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease

1 reference

12 December 2020

Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial

1 reference

12 December 2020

Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody

1 reference

12 December 2020

Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756285609356135

1 reference

2 August 2017

1 reference

2 August 2017

1 reference